Ethical Guidelines
This page lists 124 references in the Main Healthy Skepticism Library relevant to Ethical Guidelines.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL6790
Kaiser J.
Bioethics. Researchers attack newspaper probe of trials.
Science 2006 Sep 22;313(5794):1714
http://www.sciencemag.org/cgi/content/full/313/5794/1714b
HSL6788
Lassen LC, Thomsen MK.
[Global health--the ethical responsibility of the pharmaceutical industry].
Ugeskr Laeger 2006 Sep 4;168(36):2994-5
HSL6771
Sloane T.
Bad medicine. Big Pharma's cash injections lead to poor ethical outcomes.
Mod Healthc 2006 Aug 7;36(31):19
HSL6838
Young M.
They are more than just pretty people handing out cool pens.
Dermatol Nurs 2006 Aug 01;18(4):323-4
HSL6619
ACOG Committee on Ethics.
ACOG Committee Opinion No. 341 Ethical ways for physicians to market a practice
Obstet Gynecol. 2006 Jul 01;108(1):239-42
http://www.greenjournal.org/cgi/reprint/108/1/239
HSL6550
Guterman L.
Artificial-blood study has critics seeing red.
Chron High Educ 2006 Jun 16;52(41):A17
HSL6396
Pauls MA, Ackroyd-Stolarz S.
Identifying bioethics learning needs: a survey of Canadian emergency medicine residents.
Acad Emerg Med 2006 Jun 01;13(6):645-52
http://www.aemj.org/cgi/content/full/13/6/645
HSL5490
Looi YC.
Guideline overload forgets the staff needed to implement them
BMJ 2006 May 13;332(7550):1160
http://bmj.bmjjournals.com/cgi/content/short/332/7550/1160-a?etoc
HSL5749
Novas C.
What is the bioscience industry doing to address the ethical issues it faces?
PLoS Med 2006 May 01;3(5):e142
Link to source with long URL
HSL5750
Mackie JE, Taylor AD, Finegold DL, Daar AS, Singer PA.
Lessons on ethical decision making from the bioscience industry.
PLoS Med 2006 May 01;3(5):e129
Link to source with long URL
HSL5684
Wadman M.
London's disastrous drug trial has serious side effects for research.
Nature 2006 Mar 23;440(7083):388-9
http://www.nature.com/doifinder/10.1038/440388a
HSL5431
Coleman DL, Kazdin AE, Miller LA, Morrow JS, Udelsman R.
Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school's approach.
Acad Med 2006 Feb 01;81(2):154-60
Link to source with long URL
HSL5671
Friedman LS, Richter ED.
Excessive and disproportionate advertising in peer-reviewed journals.
Int J Occup Environ Health 2006 Jan-Mar 01;12(1):59-64
HSL5673
Chan CH.
The pharmaceutical role.
Acad Psychiatry 2006 Jan-Feb 01;30(1):45-7
http://ap.psychiatryonline.org/cgi/content/full/30/1/45
HSL5207
Flynn G.
The NIH ethics crackdown: a message to the research community.
Ann Emerg Med 2006 Jan;47(1):57-60
HSL5601
Almirall N.
The ethics of engagement with the pharmaceutical industry.
Mich Med 2006 Jan-Feb;105(1):10-2
HSL6562
Dresser R.
Private-sector research ethics: marketing or good conflicts management The 2005 John J. Conley Lecture on Medical Ethics
Theor Med Bioeth. 2006;27(2):115-39 2006;27(2):115-39
http://www.springerlink.com/content/bq855531108k52p6/
HSL6959
Pauer-studer H.
Public Reason and Bioethics
Medscape General Medicine. 2006;8(4):13. 2006;8(4):13
http://www.medscape.com/viewarticle/544483_print
HSL5041
Halperin SA, Scheifele D, Duval B, Ward B.
Conforming to ICMJE principles.
CMAJ 2005 Nov 22;173(11):1358-9
http://www.cmaj.ca/cgi/content/full/173/11/1358-c
HSL5262
Komesaroff PA.
Ethical issues in the relationships with industry: an ongoing challenge. New Guidelines open for public comment.
J Paediatr Child Health 2005 Nov;41(11):558-60
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1440-1754.2005.00719.x
HSL5046
Burda D.
Modern Healthcare rules. Our editorial code of ethics guides our coverage of the industry.
Mod Healthc 2005 Oct 31;35(44):18
HSL2845
Tanne JH.
US National Institutes of Health issue new ethics guidelines.
BMJ 2005 Sep 3;331(7515):472
http://bmj.bmjjournals.com/cgi/content/full/331/7515/472-b
HSL3942
Mansfield PR.
Banning all drug promotion is the best option pending major reforms.
J Bioethical Inquiry 2005;2(2):16-22
HSL4225
Timimi S.
Psychiatry has effectively become a commodity that is being sold to the drug industry.
Ment Health Today 2005 Jun 01;:21
HSL5039
Rasmussen LM.
The ethics and aesthetics of for-profit bioethics consultation.
HEC Forum 2005 Jun;17(2):94-121
HSL1853
Kaisernetwork.org
Prescription Drugs: PhRMA CEO Tauzin Discusses Drug Industry Image, Reimportation, Other Issues
kaisernetwork.org 2005 May 10
HSL1771
Solomon J.
Researchers Tested AIDS Drugs on Children
LA Times 2005 May 4
HSL4176
Diller L.
Fallout from the pharma scandals: the loss of doctors' credibility?
Hastings Cent Rep 2005 May-Jun 01;35(3):28-9
HSL4253
MacDonald A.
Ethics committee approval of multicentre studies.
Intern Med J 2005 May 01;35(5):311-2
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1445-5994.2005.00827.x
HSL5358
Sociedades Medicas-Cientificas miembros de la Asociacion de Sociedades Cientificas-Medicas de Chile.
[Recommendations to avoid conflicts of interest].
Rev Med Chil 2005 May;133(5):607-8
Link to source with long URL
HSL1854
Vesely R.
Medical group OKs ethics rules
San Gabriel Valley Tribune 2005 Apr 23
HSL4255
Komesaroff P.
Ethical issues in the relationships involving medicine and industry: evolving problems require evolving.
Intern Med J 2005 Apr 01;35(4):203-5
Link to source with long URL
HSL5472
Krishnan E.
Unregistered trials are unethical.
PLoS Med 2005 Feb 01;2(2):e48
Link to source with long URL
HSL5428
Caulfield T.
Legal and ethical issues associated with patient recruitment in clinical trials: the case of competitive enrolment.
Health Law Rev 2005;13(2-3):58-61
HSL1347
Wazana A, Granich A, Primeau F, Bhanji NH, Jalbert M.
Using the literature in developing McGill's guidelines for interactions between residents and the pharmaceutical industry.
Acad Med 2004 Nov;79(11):1033-40
http://www.academicmedicine.org/cgi/content/full/79/11/1033
HSL2818
Daikos GK.
Ethical dilemmas encountered during clinical drug trials.
Int J Antimicrob Agents 2004 Jul;24(1):24-31
Link to source with long URL
HSL4045
Sterckx S.
Patents and access to drugs in developing countries: an ethical analysis.
Developing World Bioeth 2004 May;4(1):58-75
Link to source with long URL
HSL2801
James , M. J., L. G.
Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib
J Med Ethics 2004 Apr;30(2):182-4
HSL2795
Ferris LE, Singer PA, Naylor CD.
Better governance in academic health sciences centres: moving beyond the Olivieri/Apotex Affair in Toronto.
J Med Ethics 2004 Feb;30(1):25-9
http://jme.bmjjournals.com/cgi/content/full/30/1/25
HSL5208
Malavige GN.
Doctors, drug companies and medical ethics: a Sri Lankan perspective.
Indian J Med Ethics 2004 Jan-Mar;1(1):26
HSL5209
Guha A.
A comparison of codes of pharmaceutical marketing practices.
Indian J Med Ethics 2004 Jan-Mar;1(1):19-21
HSL5213
Roy N.
Who rules the great Indian drug bazaar?
Indian J Med Ethics 2004 Jan-Mar;1(1):2-3
HSL5344
[No authors listed].
Ethical code of the pharmaceutical industry in Slovakia. (Excerpts).
Med Etika Bioet 2004 Aut;11(3-4):11-22
HSL1437
Gale EA.
Between two cultures: the expert clinician and the pharmaceutical industry.
Clin Med 2003 Nov-Dec;3(6):538-41
Link to source with long URL
HSL2107
Wager E.
Good practice in publication of clinical trial results.
Br J Psychiatry 2003 Nov;183:464-5
http://bjp.rcpsych.org/cgi/content/full/183/5/464-a
HSL5439
Kietinun S, Gupte MD, Sengupta A.
A clinical trial in a developing country: many questions, few answers.
Issues Med Ethics 2003 Jul-Sep;11(3):89-90
HSL2904
Bennett J, Collins J.
The relationship between physicians and the biomedical industries: advice from the Royal College of Physicians.
Clin Med 2002 Jul-Aug;2(4):320-2
Link to source with long URL
HSL2877
Drazen JM, Curfman GD.
Financial associations of authors.
N Engl J Med 2002 Jun 13;346(24):1901-2
http://content.nejm.org/cgi/content/full/346/24/1901
HSL2155
Romano M.
Student rally Med school attendees write ethics code on drug firms.
Mod Healthc 2002 May 13;32(19):24,
HSL2901
Bode UH, Geisler EP.
[Medical ethics as output of economically motivated industrial objectives].
Wien Med Wochenschr. 2002;152(13-14):309-12
Link to source with long URL
HSL2765
Kondro W.
Canadian university publishes new rules to protect scientists.
Lancet 2001 Apr 7;357(9262):1104
http://linkinghub.elsevier.com/retrieve/pii/S0140673600043221
HSL5441
Mamdani B, Mamdani M.
Ethics of professional advertising.
Issues Med Ethics 2001 Jan-Mar;9(1):18
HSL2989
Tenery RM Jr.
Interactions between physicians and the health care technology industry.
JAMA 2000 Jan 19;283(3):391-3
http://jama.ama-assn.org/cgi/content/full/283/3/391
HSL799
Dean M.
Guidelines for CME need revamping.
Can Fam Physician 1996 Jul;42:1295-7
HSL789
Gutkin C, Handfield-jones R.
Guidelines for CME need revamping
Can Fam Physician 1996;42:1296-1297
HSL857
Colby WD.
Guidelines for interaction with the pharmaceutical industry.
CMAJ 1995 Apr 1;152(7):1040-2
HSL847
Guyatt G.
Guidelines for interaction with the pharmaceutical industry
CMAJ 1995;152:1041-1042
HSL6272
RMI code of practice
New Zealand Medical Journal 1994;107:383
HSL6474
Forrest DM, Ruedy J.
Proposed guidelines
Annals of the Royal College of Physicians and Surgeons of Canada 1994;27:46-47
HSL6477
Gardner L.
Professional organizations and healthcare industry support: ethical conflict. Commentary
Cambridge Quarterly of Healthcare Ethics 1994;3:247-253
HSL2188
Forrest DM, Ruedy J.
Proposed guidelines for housestaff interaction with pharmaceutical companies.
Ann R Coll Physicians Surg Can 1993 Oct;26(5):291-3
HSL5697
Lober CW.
Ethics in pharmaceutical advertising.
Dermatol Clin 1993 Apr 01;11(2):285-8
HSL5540
Jablonsky G.
Physicians and the pharmaceutical industry
Canadian Medical Association Journal 1993;148:486
HSL5547
Krause J, Nour Eldin.
Ethical criteria and pharmaceutical advertising
Drugs made in Germany 1993;36(3):78-90
HSL6067
Harrison V
An overview of current guidelines for commercial support of continuing medical education
Journal of Continuing Education in the Health Professions 1993;13:68-76
HSL5143
Organon, the IFPMA Code and the WHO Ethical Criteria
MaLAM International Newsletter 1992 Dec:1-2
HSL4987
Whither WHO’s ethical criteria?
Health Horizons 1992 Oct(17):26
HSL4988
Chetley A.
Promoting health or pushing drugs?
HAI News 1992 Oct(67):1-2, 10-12
HSL4801
Camerlain M.
Three cheers for CME
Canadian Medical Association Journal 1992;146:1153
HSL4814
Davis P.
The pharmaceutical industry: a valuable CME resource
Canadian Journal of CME 1992;4(8):1-2
HSL4822
Freedman M.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992;146:329
HSL4825
Gans JA.
The need for guidelines in pharmaceutical promotion: A pharmacy perspective
Journal of Pharmaceutical Marketing & Management 1992;7(1):147-155
HSL4865
Morris LA, Griffin JP.
The evolving role of FDA in prescription drug promotion
Journal of Drug Issues 1992;22:245-256
HSL4866
Mossinghoff GJ.
Pharmaceutical manufacturers and self-regulation of drug advertising and promotion
Journal of Drug Issues 1992;22:235-243
HSL4871
Nixon AJ.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992;146(328-329)
HSL4889
Paterson AH.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992;146:328
HSL4896
Robinson LA.
Physicians and the pharmaceutical industry
Canadian Medical Association Journal 1992;147:5822-583
HSL4897
Rogers A.
EC pharmaceutical directives
Lancet 1992;339:483
HSL4937
Woollard RF.
Physicians and pharmaceutical companies
Canadian Medical Association Journal 1992;146:332
HSL4746
Huston P.
Surviving in a get-tough-on promotion climate
Medical Marketing & Media 1991 Jun;26(6):40-46, 48, 50-51
HSL4656
Fevang L.
CPhA replies
Drug Merchandising 1991;72(6):7, 9
HSL4664
Herxheimer A, Lundborg CS, Westerholm B.
Advertisements for medicines in medical journals: a collaborative international study
1991
HSL4711
Squires BP.
Stress and the ethical physician
Canadian Medical Association Journal 1991;145:1081
HSL4714
Üstel I, Herxheimer A.
Progress in medicines control
Lancet 1991;337:905-906
HSL4715
Venturelli J.
Medical ethics
Annals of the Royal College of Physicians and Surgeons of Canada 1991;24:161-162
HSL4717
Webber J.
Wine and cheese and CE: guidelines needed for industry sponsorship
Drug Merchandising 1991;72(4):33
HSL5474
Moore DL.
Recurrent issues in the review of medical research on human subjects.
Albany Law J Sci Technol 1991;1:1-33
HSL4499
MaLAM replies to IFPMA letter
Scrip 1990(1523):26
HSL4502
American Federation for Clinical Research Guidelines for Avoiding Conflict of Interest
Clinical Research 1990;38:239-240
HSL4504
Andrew M.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990;322:65
HSL4512
Ethical responsibilities of physicians in their dealings with pharmaceutical companies
Annals of the Royal College of Physicians and Surgeons of Canada 1990;23:45-48
HSL4516
Bushe CJ.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990;322:65
HSL4560
Noble RC.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990;113:408
HSL4575
Russell R, Nelson PJ, Ohri L.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990;322:64-65
HSL4588
Solomon SD.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990;322:65
HSL4589
Squires BP.
Editors and advertisers
Canadian Medical Association Journal 1990;143:167
HSL4602
Venturelli J.
Medical ethics: a dilemma at our doorstep
Annals of the Royal College of Physicians and Surgeons of Canada 1990;23:335
HSL4422
Hershfield NB.
The ethics of physician-pharmaceutical company relationships
Canadian Medical Association Journal 1989;140:10
HSL4460
Implementation of WHO’s revised drug strategy
1989
HSL4497
The basis of medical school cooperation with industry in the production of accredited continuing medical education
Journal of Continuing Education in the Health Professions 1989;10:373-375
HSL4084
Good promotional practice (GPP)
Health Action International 1988 Apr
www.haiweb.org
HSL4008
[No authors listed] Related Articles, Links Guidelines on postmarketing surveillance.
Joint committee of ABPI, BMA, CSM, and RCGP.
Br Med J (Clin Res Ed) 1988 Feb 6;296(6619):399-400
HSL4002
[No authors listed] Related Articles, Links Improving medical education in therapeutics.
Health and Public Policy Committee, American College of Physicians.
Ann Intern Med 1988 Jan;108(1):145-7
HSL4021
McGregor M.
Pharmaceutical “generosity” and the medical profession
Annals of the Royal College of Physicians and Surgeons of Canada 1988;21:289
HSL3772
Carter IE.
Canadian Psychiatric Association guidelines in relating to the pharmaceutical industry.
Can J Psychiatry 1987 Aug;32(6):476-86
http://www.cpa-apc.org/Publications/Position_Papers/Guideline.asp
HSL3970
DOH proposes regulating of drug ads
Drug Monitor 1987 Aug;2(8):3-5
HSL3899
Laurence DR.
The academic clinical pharmacologist and the Royal College of Physicians Report on the relationship between physicians and the pharmaceutical industry.
Br J Clin Pharmacol 1987 Mar;23(3):253-5
HSL3915
Smith R.
In delicto flagrante
Medical Journal of Australia 1987;146:322-323
HSL3759
Where to draw the line.
Lancet. 1986 Oct 11;2(8511):849
HSL3822
Smith R.
Doctors and the drug industry: too close for comfort.
Br Med J (Clin Res Ed) 1986 Oct 11;293(6552):905-6
HSL3771
Guidelines for drug-company-supported CME
Canadian Medical Association Journal 1986;135:384A
HSL3826
Stavem P.
Should a drug company employee edit a medical journal?
Lancet 1986;1:684
HSL3715
Harvey K, Darvall L.
Australian pharmaceutical advertising: a critique.
Med J Aust 1985 Sep 30;143(7):272-4
HSL3706
WHO meeting agrees on rational drugs strategy
Lancet 1985;2:1350-1351
HSL3636
Statement on ethical conduct in research by the Infectious Diseases Society of America.
J Infect Dis. 1984 Nov 01;150(5):792-3
HSL3667
Cousins J.
Payments to doctors and the responsibilities of ethics committees [2nd of 2 letters]
British Medical Journal 1984 Jan 28;288:323
HSL3612
Ball JG, Snell ES.
Payments to doctors and the responsibilities of ethics committees
British Medical Journal 1983 Dec 17;287:1884
HSL3585
Kass EH.
Seduction in a grand hotel
Reviews of Infectious Diseases 1983;5:973-974
HSL3541
Gass DA.
Ethical issues in sponsorship of CME
Canadian Medical Association Journal 1982;127:681
HSL3446
Wasner C, Kotzin B.
Sulindac "public relations" deplored.
N Engl J Med 1979 Feb 15;300(7):373
HSL3352
Dixon RB.
The current status of guidelines for clinical research from the viewpoint of the pharmaceutical industry.
J Clin Pharmacol 1977 Nov-Dec;17(11-12):691-6
http://jcp.sagepub.com/cgi/reprint/17/11/691
HSL3328
Helffrich S.
The broadcaster view O-T-C advertising.
J Am Pharm Assoc 1976 Sep;16(9):507-9,
HSL3323
Anonymous .
Standards in pharmaceutical advertising
Medical Journal of Australia 1976 Jun 5;63(23):855-856
HSL3341
Rucker TR.
Drug information for practitioners: commercial obligation or social responsibility?
Journal of Drug Issues 1976;6(1):43-49